MPN | Tumor

CURE’s myeloproliferative neoplasms (MPN) page is an extensive resource of cancer information featuring the latest MPN news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on myeloproliferative neoplasms.

How the Name Change to Myeloproliferative Neoplasms Affected People With the Disease

September 23rd 2022

A decision to rename myeloproliferative neoplasms led to a plethora of developments in a space where there was once little interest.

Study Will Analyze Imetelstat-Jakafi Combination for Myelofibrosis

August 30th 2022

A clinical trial recently kicked off, analyzing the combination of imetelstat plus Jakafi for the treatment of myelofibrosis, a type of rare blood cancer.

FDA Approves Pemazyre for Myeloid or Lymphoid Neoplasms With FGFR1-Rearrangements

August 26th 2022

The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement.

Ayvakit Improves Disease Burden, Quality of Life in Mastocytosis

August 23rd 2022

Treatment with Ayvakit was associated with promising outcomes in patients with mastocytosis, according to findings from the PIONEER trial.

FDA OKs New Drug Application for Momelotinib to Treat Myelofibrosis

August 18th 2022

The FDA has set a date to decide whether or not to approve momelotinib for myelofibrosis, a rare type of blood cancer.

‘Listen to Your Patient,’ Says Cancer Caregiver

July 22nd 2022

A cancer caregiver recommends that other caregivers become well-versed in their loved one’s disease.

Cancer Caregiver Realizes the Impact of His Advocacy Work

July 18th 2022

When Jeff Bushnell was contacted by a patient with an MPN who lived in the Philippines, he realized how his advocacy work was impacting patients around the globe.

Oncologist Who Specializes in Treating Rare Blood Cancers ‘Learns from Patients Every Day’

July 15th 2022

An expert from the Tisch Cancer Institute discusses how he learns from patients and their caregivers, and how their insight has helped lead advancements in the treatment of myeloproliferative neoplasms, a group of rare blood cancers.

‘I Want to Die With This, Not Because of It,’ Says Survivor of Rare Blood Cancer

July 8th 2022

Kerry Fraser, a survivor of a myeloproliferative neoplasm and retired NHL referee, explained how he came to be diagnosed, and his hopes for the future of the group of rare blood cancers.

Positive Attitude, Paired With the Right Treatment Plan Can Have a ‘Medicinal Effect’ for MPNs

July 5th 2022

Social support and maintaining a positive attitude are crucial when facing a diagnosis of a myeloproliferative neoplasm, according to a caregiver and health care provider.

Science Surrounding MPNs ‘Continues to Evolve at a Rapid Pace’

July 1st 2022

Dr. John Mascarenhas discusses the progress of the research around myeloproliferative neoplasms , as well as what more efforts are still needed.

An Introduction to the 2021 MPN Heroes®

June 29th 2022

Sierra Oncology Submits Application Seeking FDA Approval of Momelotinib to Treat Myelofibrosis

June 21st 2022

Sierra Oncology noted in a company-issued press release that if momelotinib is approved by the FDA that they anticipate making the drug available to patients with myelofibrosis next year.

Patients With MPNs Must Be Honest About Their Symptoms, Says Expert

June 20th 2022

It is incredibly important that patients with MPNs inform their health care team of any symptoms they are experiencing, according to an expert from The Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center.

Tom Brady Dyes Hair Orange to Raise Funds for Pediatric Cancer, Cancer Choir With a Profane Name Performs for Pope Francis and More

June 10th 2022

From Tampa Bay Buccaneers quarterback Tom Brady letting children with cancer dye his hair orange to the name of a cancer drug causing controversy at the Scripps National Spelling Bee, here’s what’s happening in the cancer space this week.

Treatment With Vonjo May Elicit Fewer Side Effects Than Other Available Therapies in Myelofibrosis, a Rare Type of Blood Cancer

June 4th 2022

Vonjo proved to have a similar, or superior, side effect profile compared with the best available therapy for patients with myelofibrosis, a form of blood cancer.

Myelofibrosis Symptom Management Is ‘Incredibly Important’ to Preserve Quality of Life

May 24th 2022

Myelofibrosis may cause major impairments to a patient’s quality of life, which is why it is pertinent that patients work with their clinicians to address these side effects.

Educated Patient® MPN Summit Disease Approaches Panel: May 7, 2022

May 24th 2022

Watch Dr. Jamile Shammo and Dr. Srdan Vestovsek answer questions about disease approaches during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Novel Agents & Clinical Trials in Myelofibrosis Presentation: May 7, 2022

May 23rd 2022

Watch Dr. Srdan Vestovsek, from The University of Texas MD Anderson Cancer Center, discuss novel agents and clinical trials in myelofibrosis, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Differentiating an Essential Thrombocythemia Diagnosis Presentation: May 7, 2022

May 22nd 2022

Watch Dr. Jamile Shammo, from Rush University Medical Center, discuss differentiating an essential thrombocythemia diagnosis, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Focus on Clinical Trials Panel: May 7, 2022

May 21st 2022

Watch Dr. Jamile Shammo, Dr. Angela Fleishman and Kapila Viges answer questions about clinical trials during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Clinical Trials Presentation: May 7, 2022

May 20th 2022

Watch Kapila Viges, from the MPN Research Foundation, discuss clinical trials, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Novel Agents and Clinical Trials in Polycythemia Vera Presentation: May 7, 2022

May 19th 2022

Watch Dr. Angela Fleishman, from the University of California Irvine, discuss novel agents and clinical trials in polycythemia vera, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Diagnoses and Treatment Panel: May 7, 2022

May 18th 2022

Watch Dr. Jamile Shammo, Dr. Aaron Gerds and Dr. Bart Scott, answer questions during the diagnoses and treatment panel during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Current Treatment Options Presentation: May 7, 2022

May 17th 2022

Watch Dr. Bart Scott, from Fred Hutchinson Cancer Center, discuss current treatment options, during the CURE Educated Patient MPN Summit.

Educated Patient® MPN Summit Approach to Diagnosing & Assessing Symptoms Presentation: May 7, 2022

May 16th 2022

Watch Dr. Aaron Gerds, from Cleveland Clinic Taussig Cancer Institute, discuss approaches to diagnosing and assessing symptoms, during the CURE Educated Patient MPN Summit.

10-Year-Old Child With Cancer Sworn in as Honorary Member of NYPD, Experts Suggest a New Name for Certain Prostate Cancers and More

April 22nd 2022

From Philadelphia Flyers’ employees suing the organization after developing a rare blood cancer to experts proposing a new name for low-risk prostate cancer and an actor on Disney+’s “The Mandolorian” dying of cancer, here’s what is happening in the cancer space this week.

Healthy Pregnancy Is ‘Definitely’ Possible for Women With MPNs

April 18th 2022

Patients with myeloproliferative neoplasms, a group of blood cancers, who plan to conceive should talk with their doctor about their obstetric and medical history and risk of complications, according to an expert.

Highlights and Key Takeaways from the 2021 MPN Roundtable

March 14th 2022

Cancer Advocacy Helps Ease Nerves and Uncertainty, Says One Patient

March 14th 2022

A patient’s experience with polycythemia vera — a rare blood cancer — led to her becoming an advocate for others to help ease all the nerves and uncertainty that many patients face when they hear they have cancer.